Survival Analysis of Patients with Triple-Negative Breast Cancer: A Single-Center Experience
Received Date : 17 Mar 2022
Accepted Date : 28 Jun 2022
Available Online : 01 Aug 2022
Doi: 10.37047/jos.2022-89749 - Article's Language: EN
J Oncol Sci. 2022;8(2):94-9
This is an open access article under the CC BY-NC-ND license
Objective: We determined the prognostic factors of patients with triple-negative breast cancer. Material and Method: Two hundred thirteen female patients with triple-negative breast cancer (TNBC) followed in the medical oncology unit of Kartal Doctor Lütfi Kırdar City Hospital between 2005 and 2020 were evaluated retrospectively. Patients’ clinical and demographic features, laboratory findings, and treatments were investigated and their effect on mortality was analyzed. Results: The median age of patients was 52 years. Relapse was observed in 46 (26.6%) patients, 127 patients were followed without progression. During the follow-up period, 57 patients died and 156 patients survived. The median overall survival was 137.2 months in patients with tumor size <2 cm, 109.9 months in patients with ≥2 cm and <5 cm, and 90.5 months in patients with ≥5 cm (p=0.02). Tumor diameter, lymph node positivity, menopausal status, and whether receiving neoadjuvant chemotherapy were determined as factors affecting the overall survival. Conclusion: In accordance with the literature, patients with TNBC showed more aggressive characteristics. Our findings support that TNBC is a heterogeneous disease and highlight the need to define molecular subclasses. We believe that demographic and prognostic data studies with large patient series and determining molecular markers will guide the follow-up and treatment of patients with TNBC.
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [Crossref]  [PubMed] 
  2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. [Crossref]  [PubMed]  [PMC] 
  3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423. [Crossref]  [PubMed]  [PMC] 
  4. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005;7(4):143-148. [Crossref]  [PubMed]  [PMC] 
  5. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32. [Crossref]  [PubMed] 
  6. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49(1):22-34. [Crossref]  [PubMed] 
  7. Gonçalves H Jr, Guerra MR, Duarte Cintra JR, Fayer VA, Brum IV, Bustamante Teixeira MT. Survival study of triple-negative and non-triple-negative breast cancer in a Brazilian cohort. Clin Med Insights Oncol. 2018;12:1179554918790563. [Crossref]  [PubMed]  [PMC] 
  8. Qiu J, Xue X, Hu C, et al. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer. 2016;7(2):167-173. [Crossref]  [PubMed]  [PMC] 
  9. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309-330. [Crossref]  [PubMed]  [PMC] 
  10. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-187. [Crossref]  [PubMed] 
  11. Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, Rossing M. Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort. Acta Oncol. 2018;57(1):51-57. [Crossref]  [PubMed] 
  12. Bulut N, Aksoy S, Dizdar O, et al. Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol. 2011;28 Suppl 1:S75-79. [Crossref]  [PubMed] 
  13. Akdeniz A, Altundağ ÖÖ. Üçlü negatif meme kanserlerinin klinik ve demografik verileri-tek merkez deneyimi [Clinical and pathological characteristics of triple-negative breast cancer patients: A single-center experience]. Mersin Univ Saglık Bilim Derg. 2019;12(3):478-488. [Crossref] 
  14. Haiderali A, Rhodes WC, Gautam S, et al. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer. Future Oncol. 2021;17(29):3819-3831. [Crossref]  [PubMed] 
  15. Polley MC, Leon-Ferre RA, Leung S, et al. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat. 2021;185(3):557-566. [Crossref]  [PubMed]  [PMC] 
  16. Rapiti E, Pinaud K, Chappuis PO, et al. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study. Cancer Med. 2017;6(3):526-536. [Crossref]  [PubMed]  [PMC] 
  17. Urru SAM, Gallus S, Bosetti C, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018;18(1):56. [Crossref]  [PubMed]  [PMC] 
  18. Costa REARD, Oliveira FTR, Araújo ALN, Vieira SC. Prognostic factors in triple-negative breast cancer: a retrospective cohort. Rev Assoc Med Bras (1992). 2021;67(7):950-957. [Crossref]  [PubMed] 
  19. Kwon J, Eom KY, Koo TR, et al. A prognostic model for patients with triple-negative breast cancer: importance of the modified nottingham prognostic index and age. J Breast Cancer. 2017;20(1):65-73. [Crossref]  [PubMed]  [PMC] 
  20. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES; Korean Breast Cancer Society. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat. 2010;123(1):177-187. [Crossref]  [PubMed] 
  21. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer-prognostic factors and survival. Radiol Oncol. 2011;45(1):46-52. [Crossref]  [PubMed]  [PMC] 
  22. He M, Zhang JX, Jiang YZ, et al. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget. 2017;8(27):44870-44880. [Crossref]  [PubMed]  [PMC] 
  23. Aleskandarany MA, Green AR, Benhasouna AA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3. [Crossref]  [PubMed]  [PMC] 
  24. Denkert C, Loibl S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24(11):2786-2793. [Crossref]  [PubMed] 
  25. Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22. [Crossref]  [PubMed]  [PMC] 
  26. Munzone E, Botteri E, Sciandivasci A, et al. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat. 2012;134(1):277-282. [Crossref]  [PubMed] 
  27. Abubakar M, Orr N, Daley F, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18(1):104. [Crossref]  [PubMed]  [PMC]